

Culture profile and antibiogram of infective organisms from endotracheal secretions in mechanically ventilated patients of a tertiary care centre

¹Dr. Jayesh T. Kuvar, Department of Microbiology, M.P. Shah Government Medical College, Jamnagar

²Dr. Rashmika D. Parmar, Department of Microbiology, M.P. Shah Government Medical College, Jamnagar

³Dr. Krunal D. Mehta, Department of Microbiology, M.P. Shah Government Medical College, Jamnagar

⁴Dr. Hitesh K. Shingala, Department of Microbiology, M.P. Shah Government Medical College, Jamnagar

Corresponding Author: Dr. Jayesh T. Kuvar, Department of Microbiology, M.P. Shah Government Medical College, Jamnagar

How to citation this article: Dr. Jayesh T. Kuvar, Dr. Rashmika D. Parmar, Dr. Krunal D. Mehta, Dr. Hitesh K. Shingala, "Culture profile and antibiogram of infective organisms from endotracheal secretions in mechanically ventilated patients of a tertiary care centre", IJMACR- January - 2026, Volume – 9, Issue - 1, P. No. 118 – 126.

Open Access Article: © 2026 Dr. Jayesh T. Kuvar, et al. This is an open access journal and article distributed under the terms of the creative common's attribution license (<http://creativecommons.org/licenses/by/4.0>). Which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Introduction: Mechanical ventilation, while life-saving, increases the risk of ventilator-associated pneumonia (VAP), commonly due to colonization of the lower respiratory tract by multidrug-resistant pathogens. Understanding local microbial patterns and resistance profiles is critical for optimizing empirical therapy and improving ICU outcomes.

Aims and Objectives

- To analyzed the culture profile and antibiogram of infective organisms isolated from endotracheal secretions in mechanically ventilated patients.
- To Approval for the study was obtained from the Institutional Ethics Committee, and written informed consent was secured from the patients' caregivers or legal representatives.

Material and Method:

Study Design: Cross Sectional Study

Study Period: The study was conducted over six months June 2023–November 2023.

Study Place: Department of Microbiology, M.P. Shah Government Medical College, Jamnagar, Gujarat.

Sample Size: Total sample size 113.

Study Population: Patients scheduled for elective microbiology laboratory

Sampling Method: Susceptibility Testing

Result: In total, 113 samples were processed. tracheal aspirates were 113, with males (47/113) outnumbered females (26/113). Out of a total of 113 samples, 73 (64.40%) were culture-positive and 40 (36.60%) were sterile. *Acinetobacter* spp. was the most common pathogen among 72 culture positives (27/73, 36.98%),

followed by *Klebsiella* spp. (21/73, 28.50%), *Pseudomonas* spp. (13/73, 17.80%), and *Escherichia coli* (8/73, 9.59%) and *Staphylococcus aureus* (6/73, 8.22%).

Conclusion: The study highlights the growing prevalence of multidrug-resistant pathogens in ventilated ICU patients, emphasizing the need for ongoing microbiological surveillance and judicious antimicrobial use to reduce morbidity and mortality.

Keywords: Ventilator-associated pneumonia, Endotracheal aspirate, Antibiogram, Multidrug resistance, ICU infections, *Acinetobacter*, *Klebsiella*

Introduction

Mechanical ventilation is a critical intervention in intensive care units (ICUs), often necessitated by respiratory failure, severe infections, or post-operative support. However, prolonged mechanical ventilation is associated with an increased risk of nosocomial infections, particularly ventilator-associated pneumonia (VAP). These infections result from the colonization of the endotracheal tube and respiratory tract by pathogenic microorganisms, which can lead to significant morbidity, extended hospital stays, and increased mortality rates. Understanding the culture profile and resistance patterns of infective organisms from endotracheal secretions is vital for guiding effective antimicrobial therapy.¹

The emergence of multidrug-resistant (MDR) organisms in mechanically ventilated patients further complicates the management of these infections. Common pathogens include *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Escherichia coli*, which often exhibit resistance to first-line antibiotics. This alarming trend underscores the need for regular surveillance of the microbiological spectrum and antibiogram of organisms isolated from endotracheal secretions.

In this study, we aim to analyze the culture profile and antibiogram of infective organisms isolated from endotracheal secretions in mechanically ventilated patients at a tertiary care center.²

Aims and Objectives

- To analyzed the culture profile and antibiogram of infective organisms isolated from endotracheal secretions in mechanically ventilated patients.
- To Approval for the study was obtained from the Institutional Ethics Committee, and written informed consent was secured from the patients' caregivers or legal representatives.

Material and Method:

Study Design: Cross Sectional Study

Study Period: The study was conducted over six months June 2023–November 2023.

Study Place: Department of Microbiology, M.P. Shah Government Medical College, Jamnagar, Gujarat.

Sample Size: Total sample size 113.

Study Population: Patients scheduled for elective microbiology laboratory

Sampling Method: Susceptibility Testing

Inclusion Criteria

The study included all patients aged who were mechanically ventilated for more than 48 hours for various clinical indications, such as respiratory failure, sepsis, or post-operative management.

Exclusion Criteria

Patients with existing pulmonary infections prior to mechanical ventilation or those on antibiotics before sample collection were excluded. A total of 48 patients meeting the inclusion criteria were enrolled in the study.

Data Analysis

All data were recorded in a structured proforma and analyzed using SPSS software (version 22.1).

Descriptive statistics were employed to summarize demographic details, microbiological findings, and antibiogram results. Categorical variables were expressed as frequencies and percentages, while continuous variables were presented as means with standard deviations. Associations between clinical and microbiological parameters were analyzed using chi-

square or Fisher's exact tests, with a significance threshold set at $p < 0.05$.


Result

Out of 113 pus samples received for culture and sensitivity in the microbiology laboratory, 73 (64.40%) samples yielded positive culture, and there was no growth in 40 (35.60%) samples.

Table 1: Age Distribution

Age (years)	Number of cases (n)	Percentage (%)
<1	41	56.17%
15–50	15	20.55%
>60	17	23.28%
Total	73	100%

Graph 1: Age Distribution




This indicates that the majority of positive cultures occurred in infants under one year, highlighting the vulnerability of this age group to lower respiratory and other infections.

Table 2: Gender Distribution

Sex	Number of cases (n)	Percentage (%)
Male	47	64.38%
Female	26	35.62%
Total	73	100%

Graph 2: Gender Distribution




The gender distribution reveals a significant male predominance in culture-positive lower respiratory tract infections, with males accounting for 64.38% (47 cases) compared to females at 35.62% (26 cases), resulting in a male-to-female ratio of approximately 1.8:1.

Table 3: Distribution of Isolated Organisms

Sr. No.	Organism	Number (%)
1	Acinetobacter spp.	27 (36.98%)
2	Klebsiella pneumoniae	21 (28.50%)
3	Pseudomonas aeruginosa	13 (17.80%)
4	Escherichia coli	7 (9.59%)
5	Staphylococcus aureus	6 (8.22%)
Total		73 (100%)

Graph 3: Distribution of Isolated Organisms



- *Acinetobacter* spp. dominates the isolates, comprising 36.98% of culture-positive cases, reflecting its robust survival in ICU settings and resistance to disinfection.
- *Klebsiella pneumoniae* accounts for 28.50%, underscoring its high prevalence and ESBL-mediated resistance concerns in hospital-acquired pneumonia.
- *Pseudomonas aeruginosa* represents 17.80%, consistent with its device-associated infection profile and biofilm-forming capacity.
- *Escherichia coli* (8.50%) and *Staphylococcus aureus* (8.22%) are less frequent but clinically significant; *E. coli*'s gut translocation and *S. aureus*'s MRSA outbreaks warrant continued vigilance.

Table 4: Antimicrobial Susceptibility Pattern of *Staphylococcus aureus*

Antibiotic	No. of isolates	Percentage
Azithromycin	2	33.3%
Erythromycin	2	33.3%
Clindamycin	5	83.33%
Cefoxitin	1	16.6%
Doxycycline	5	83.33%
Minocycline	5	83.33%
Tetracycline	2	33.3%
Linezolid	6	100%
Ciprofloxacin	4	66.6%
Levofloxacin	4	66.6%
Gentamicin	2	33.3%
Total Isolate:	6	

Efficacy was highest for meropenem and imipenem (85.7%), followed by piperacillin/tazobactam (71.4%) and amikacin (71.4%). Moderate activity was seen with ampicillin-sulbactam and gentamicin (57.1% each). First-line beta-lactams and beta-lactam/β-lactamase inhibitors showed variable efficacy (ampicillin 14.3%; amoxicillin-clavulanate 28.6%; ceftriaxone, cefotaxime, cefuroxime, cefepime, cefoxitin 42.9% each). Fluoroquinolones and cotrimoxazole were less active (28.6% each). These patterns underscore prioritizing carbapenems, piperacillin/tazobactam, and aminoglycosides for empirical therapy.

Antibiotic Class Sensitivity Comparison and *Acinetobacter* Spp

Table 5: Aminoglycosides

Antibiotic	Present Study	Sharma et al.	Snehitha et al.
Amikacin	29.6%	22%	35%
Gentamicin	29.6%	22%	35%


Aminoglycoside susceptibility remains low in this cohort, contrasting with literature (22–35%). likely due to prevalent modifying enzymes.⁴

Table 6: Comparative Analysis between Antibiotic of *Acinetobacter* spp.

Antibiotic	Present Study	Sharma et al.	Snehitha et al.	Mangioni et al.	Mukherjee et al.	Swati et al.	Kanipakam et al.
Amikacin	29.6%	22%	35%	—	—	—	—
Gentamicin	29.6%	22%	35%	—	—	—	—
Piperacillin-Tazobactam	66.6%	—	—	67.7%	67.7%	67.7%	—
Ceftazidime	92.6%	—	—	94.4%	94.4%	94.4%	94.4%
Aztreonam	100%	—	—	87.8%	—	—	—
Imipenem	59.3%	—	61.1%	—	61.1%	61.1%	61.1%
Meropenem	85.2%	—	87.5%	85.4%	87.5%	87.5%	87.5%
Ciprofloxacin	14.8%	18%	—	—	12.5%	12.5%	12.5%
Doxycycline	100%	100%	100%	100%	—	—	—
Minocycline	100%	100%	100%	100%	—	—	—

Acinetobacter spp. shows uniformly low aminoglycoside susceptibility (29.6% vs. 22–35%), moderate piperacillin-Tazobactam activity (66.6% vs. 67.7%), and excellent ceftazidime (92.6% vs. 94.4%) and aztreonam (100% vs. 87.8%) efficacy. Imipenem activity is concerningly low (59.3% vs. 61.1%), while meropenem remains robust (85.2% vs. 87.5%). Fluoroquinolones are ineffective (14.8% vs. 12.5–18%). Tetracyclines maintain universal activity (100%).

Graph 4: Comparative Analysis between Antibiotic



Discussion

In this study, endotracheal secretions were sent for bacteriological culture and sensitivity to recognize the

organisms which would help in initiating and/or modifying antibiotic therapy appropriately and help in preventing the occurrence of ventilator associated

pneumonia (VAP) or Hospital acquired pneumonia (HAP) and helps bring about favourable outcome. This study to determine the culture profile and antibiogram of infective organisms from endotracheal secretions in mechanically ventilated patients at a tertiary care centre. Total 113 samples were processed tracheal aspirates were 113, with males (47/113) outnumbered females (26/113). Out of a total of 113 samples, 73 (64.40%) were culture-positive and 40 (36.60%) were sterile. *Acinetobacter* spp. dominates the isolates, comprising 36.98% of culture-positive cases, reflecting its robust survival in ICU settings and resistance to disinfection. Efficacy was highest for meropenem and imipenem (85.7%), followed by piperacillin/tazobactam (71.4%) and amikacin (71.4%). Moderate activity was seen with ampicillin-sulbactam and gentamicin (57.1% each). *Acinetobacter* spp. shows uniformly low aminoglycoside susceptibility (29.6% vs. 22–35%), moderate piperacillin–tazobactam activity (66.6% vs. 67.7%), and excellent ceftazidime (92.6% vs. 94.4%) and aztreonam (100% vs. 87.8%) efficacy.

Conclusion

The study highlights the growing prevalence of multidrug-resistant pathogens in ventilated ICU patients, emphasizing the need for ongoing microbiological surveillance and judicious antimicrobial use to reduce morbidity and mortality. Ventilated patients represent a population at risk of developing ventilator-associated pneumonia and subsequent mortality. Bacteriological and antibiogram analysis of endotracheal secretions in these subjects serves as an effective tool for monitoring the hospital's infection control and antibiotic stewardship programs and identifying temporal trends that impact patient management decisions.

References

1. Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. *Clin Microbiol Rev.* 2006 Oct;19(4):637–57.
2. Alharbi MS, Moursi SA, Alshammari A, Aboras R, Rakha E, Hossain A, et al. Multidrug-resistant *Pseudomonas aeruginosa*: Pathogenesis, resistance mechanisms, and novel therapeutic strategies. *Virulence.* 2025 Dec;16(1):2580160.
3. Mukherjee S, Misra RN, Jadhav S, Das NK, Mirza SB. Culture Profile And Antibiogram Of Infective Organisms From Endotracheal Secretions In Mechanically Ventilated Patients Of A Tertiary Care Centre. *Biop.* 2018 Mar 30;10(3):1066.
4. Snehitha K, Swapna S, Kamala P. Bacteriological Profile And Antibiogram Of Gram-Negative Bacilli Isolated From Endotracheal Tube Secretions And Tracheal Aspirates From Patients On Mechanical Ventilation: A Hospital-Based Cross-Sectional Study. *Int J Curr Pharm Sci.* 2024 July 15;106–8.
5. Sharma K, Gupta S, Sharma S, Sharma P. Antibiogram of Bacterial Isolates from Endotracheal Aspirates in a Tertiary Care Hospital in North India. *IntJCurrMicrobiolAppSci.* 2019 June 20;8(06):2562–7.
6. Sava M, Vintila BI, Bereanu AS, Fratila AM, Codru IR. Lessons from Four Years (2021-2024) of *Klebsiella pneumoniae* Resistance Surveillance Epidemiological Trends in a Romanian Intensive Care Unit. *Antibiotics (Basel).* 2025 Aug 12;14(8):825.
7. Indian Network for Surveillance of Antimicrobial Resistance (INSAR) group, India. Methicillin resistant *Staphylococcus aureus* (MRSA) in India:

prevalence & susceptibility pattern. Indian J Med Res. 2013 Feb;137(2):363–9.

8. Swati A. Microbiological spectrum and antimicrobial susceptibility patterns of various isolates from endotracheal tube aspirates in a tertiary care hospital, Hyderabad, Telangana. IJMR. 2020 Dec 28;5(2):202–7.
9. Kanipakam VK, Thoti H, Sharabu Y, Valluri AL, Gunti R. Bacteriological Study Of Ventilator-Associated Pneumonia And Antibiotic Susceptibility Of Isolates. Int J Curr Pharm Sci. 2024 Mar 15;112–6.
10. Mangioni D, Panigada M, Palomba E, Bobbio C, Chatenoud L, Alagna L, et al. Incidence, microbiological and immunological characteristics of ventilator-associated pneumonia assessed by bronchoalveolar lavage and endotracheal aspirate in a prospective cohort of COVID-19 patients: CoV-AP study. Crit Care. 2023 Sept 26;27(1):369.
11. Ferous S, Anastassopoulou C, Pitiriga V, Vrioni G, Tsakris A. Antimicrobial and Diagnostic Stewardship of the Novel β -Lactam/ β -Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacteriales Species and *Pseudomonas aeruginosa*. Antibiotics (Basel). 2024 Mar 21;13(3):285.
12. Liao Q, Yi X, Yuan Y, Zhang W, Deng J, Wu S, et al. Blood-rsCDM: a new rapid and simplified carbapenemase detection method for detecting carbapenemases in Enterobacteriales directly from positive blood cultures. BMC Microbiol. 2024 Oct 16;24(1):410.
13. Pereira JG, Fernandes J, Duarte AR, Fernandes SM. β -Lactam Dosing in Critical Patients: A Narrative Review of Optimal Efficacy and the Prevention of Resistance and Toxicity. Antibiotics (Basel). 2022 Dec 18;11(12):1839.
14. Chavali S, Menon V, Shukla U. Hand hygiene compliance among healthcare workers in an accredited tertiary care hospital. Indian J Crit Care Med. 2014 Oct;18(10):689–93.
15. Ling ML, Apisarnthanarak A, Thu LTA, Villanueva V, Pandjaitan C, Yusof MY. APSIC Guidelines for environmental cleaning and decontamination. Antimicrob Resist Infect Control. 2015;4:58.
16. Jung J, Park JH, Yang H, Lim YJ, Kim EO, Lim CM, et al. Active surveillance testing to reduce transmission of carbapenem-resistant, gram-negative bacteria in intensive care units: a pragmatic, randomized cross-over trial. Antimicrob Resist Infect Control. 2023 Mar 3;12(1):16.
17. Chung GW, Wu JE, Yeo CL, Chan D, Hsu LY. Antimicrobial stewardship: a review of prospective audit and feedback systems and an objective evaluation of outcomes. Virulence. 2013 Feb 15;4(2):151–7.
18. Yoshikawa A, Ohtsuka H, Aoki K, Tashiro N, Togo S, Komaba K, et al. Simulation-based infection prevention and control training for medical and healthcare students: a systematic review. Front Med (Lausanne). 2025;12:1529557.
19. Geng Y, Liu Z, Ma X, Pan T, Chen M, Dang J, et al. Infection prevention and control measures for multidrug-resistant organisms: a systematic review and network meta-analysis. Infection. 2025 Oct;53(5):1789–800.
20. Majumder MAA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, et al. Antimicrobial Stewardship: Fighting Antimicrobial Resistance and

Protecting Global Public Health. Infect Drug Resist.

2020;13:4713–38.

21. Kalın G, Alp E, Chouaikhi A, Roger C. Antimicrobial Multidrug Resistance: Clinical Implications for Infection Management in Critically Ill Patients. *Microorganisms*. 2023 Oct 16;11(10):2575.